<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447485</url>
  </required_header>
  <id_info>
    <org_study_id>CVAL489K1101</org_study_id>
    <nct_id>NCT01447485</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients</brief_title>
  <official_title>A Multicenter, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Valsartan in Japanese Pediatric Patients 6 to 14 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics and safety following single dose of valsartan in&#xD;
      Japanese pediatric patients with hypertension, chronic kidney disease, or nephrotic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of valsartan in plasma</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of valsartan in plasma</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of valsartan in plasma</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of valsartan in plasma</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of valsartan in plasma</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECG evaluations</measure>
    <time_frame>24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard clinical laboratory evaluations</measure>
    <time_frame>24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>2, 4, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Valsartan 20 mg or 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan (VAL489)</intervention_name>
    <arm_group_label>Valsartan 20 mg or 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese pediatric patients with hypertension, chronic kidney disease, or nephrotic&#xD;
             syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  GFR &lt; 30 mL/min/1.73 m2&#xD;
&#xD;
          -  Inability to safely tolerate the temporary discontinuation of concomitant&#xD;
             antihypertensive medications (expect amlodipine or atenolol) from 24 hours prior to&#xD;
             study drug administration to study completion.&#xD;
&#xD;
          -  Inability to safely tolerate the temporary discontinuation of any drug known or&#xD;
             suspected to effect hepatic or renal clearance capacity from 24 hours prior to study&#xD;
             drug administration to study completion (this includes drugs that are known to cause&#xD;
             induction or inhibition of hepatic enzymes).&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=6883</url>
    <description>Results for CVAL489K1101 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>August 31, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension, chronic kidney disease</keyword>
  <keyword>nephrotic syndrome</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

